TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18204042

Group type: EXPERIMENTAL
Intervention: Hypoglycaemia (nadir P-glucose 2.7 +/- 0.5 mmol/L)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Hypoxaemia (nadir pO2 5.8 +/- 0.5 kPa)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Normoglycaemic normoxia (control day)
Number of subjects: 20
Study: 17406167

Group type: EXPERIMENTAL
Intervention: Lidocaine patch 5%
Number of subjects: 100

Group type: COMPARATOR
Intervention: Naproxen 500 mg twice daily
Number of subjects: 100
Study: 14657064

Group type: EXPERIMENTAL
Intervention: Calcium antagonist strategy (CAS) - verapamil sustained release
Number of subjects: 22576

Group type: COMPARATOR
Intervention: Non-calcium antagonist strategy (NCAS) - atenolol
Number of subjects: 22576
Study: 11049918

Group type: EXPERIMENTAL
Intervention: Droperidol (0.625 mg IV)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Ondansetron (4 mg IV)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Promethazine (12.5 mg IV)
Number of subjects: 150
Study: 8713784

Group type: EXPERIMENTAL
Intervention: Intralipid 20% infusion (n = 5)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Dextrose 5% infusion (n = 5)
Number of subjects: 10
Study: 1569339

Group type: EXPERIMENTAL
Intervention: Low-dose amphotericin B (serum concentrations of 0.2-0.4 microgram/ml)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-dose amphotericin B
Number of subjects: 0
Study: 3535521

Group type: EXPERIMENTAL
Intervention: 1 gm of ampicillin intravenously every 6 hours until delivery
Number of subjects: 1207

Group type: COMPARATOR
Intervention: Not treated (control group)
Number of subjects: 1207
Study: 29669617

Group type: EXPERIMENTAL
Intervention: Modified mindfulness-based cognitive therapy (MBCT) course, comprising eight weekly 2-hour sessions with homework (mindfulness practice) between sessions.
Number of subjects: 22
Study: 27923865

Group type: EXPERIMENTAL
Intervention: Home-based smoking prevention program targeting smoking-specific parenting (n=684)
Number of subjects: 1398

Group type: COMPARATOR
Intervention: Basic information about youth smoking (Control group, n=714)
Number of subjects: 1398
Study: 24955850

Group type: EXPERIMENTAL
Intervention: Spanish M-FAST (uncoached condition)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Spanish M-FAST (coached condition)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Spanish M-FAST (honest condition)
Number of subjects: 102
Study: 22231543

Group type: EXPERIMENTAL
Intervention: Dorsal genital nerve (DGN) stimulation at an amplitude of 51 mA (range 30-64), pulse width: 200 μs, pulse rate: 20 Hz
Number of subjects: 7
Study: 20420997

Group type: EXPERIMENTAL
Intervention: Intramuscular vaccination in deltoid muscle
Number of subjects: 185

Group type: COMPARATOR
Intervention: Intramuscular vaccination in vastus lateralis
Number of subjects: 185
Study: 18524727

Group type: EXPERIMENTAL
Intervention: Propafenone (300 mg/day)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Sotalol (80 mg/day)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Amiodarone (400 mg/day)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Diltiazem (180 mg/day)
Number of subjects: 180

Group type: COMPARATOR
Intervention: No anti-arrhythmic drugs (Control Group)
Number of subjects: 180
Study: 15954962

Group type: EXPERIMENTAL
Intervention: NFSC (number of fluctuations in the skin conductance per second)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: NFSC
Number of subjects: 14
Study: 12649315

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Physostigmine
Number of subjects: 0
Study: 10608204

Group type: EXPERIMENTAL
Intervention: Dextromethorphan (DM) 40 mg and chlorpheniramine maleate (CPM) 20 mg i.m.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group received 20 mg CPM i.m. alone
Number of subjects: 60
Study: 8717577

Group type: EXPERIMENTAL
Intervention: Cytobrush plus Ayre spatula
Number of subjects: 346

Group type: EXPERIMENTAL
Intervention: Cervex brush
Number of subjects: 346

Group type: COMPARATOR
Intervention: cotton swab plus Ayre spatula
Number of subjects: 346
Study: 1682541

Group type: EXPERIMENTAL
Intervention: Outer membrane vesicle vaccine
Number of subjects: 171800

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 171800
Study: 7023791

Group type: EXPERIMENTAL
Intervention: 15 ml of aluminum hydroxide gel (fasting)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 10 ml magnesium hydroxide suspension (fasting)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 15 ml of aluminum hydroxide gel (fed)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 15 ml of aluminum hydroxide/magnesium hydroxide mixture (fed)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Fasted, no antacid
Number of subjects: 12

Group type: COMPARATOR
Intervention: Fed, no antacid
Number of subjects: 12
Study: 31926812

Group type: COMPARATOR
Intervention: Bifocal‐Sham
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: ActiSham
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Multifocal‐tDCS
Number of subjects: 13

Group type: COMPARATOR
Intervention: Bifocal‐tDCS
Number of subjects: 13

Group type: COMPARATOR
Intervention: Sham (Bifocal‐tDCS)
Number of subjects: 13
Study: 31269786

Group type: EXPERIMENTAL
Intervention: Mesh nebulizer (MN)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Jet nebulizer (JN)
Number of subjects: 31
Study: 28103623

Group type: EXPERIMENTAL
Intervention: Fenofibrate (FENO) co-incubation with excess fatty acid (24hFA) in HSkMC from obese subjects
Number of subjects: 31

Group type: COMPARATOR
Intervention: Excess fatty acid (24hFA) treatment
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Fenofibrate treatment in vivo
Number of subjects: 31
Study: 26374702

Group type: EXPERIMENTAL
Intervention: subcutaneous interferon (IFN) β‐1a
Number of subjects: 290
Study: 24016566

Group type: EXPERIMENTAL
Intervention: Transfected group (recombinant lentiviral vector encoding miR-15a/16-1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transfected-radiotherapy group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Radiotherapy group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transfected group
Number of subjects: 0
Study: 21632446

Group type: EXPERIMENTAL
Intervention: Bio-impedance-guided volume management
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Vitamin D(3) 50,000 U weekly for 8 doses, then 10,000 U weekly
Number of subjects: 70

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 70

Group type: COMPARATOR
Intervention: Matching placebo for vitamin D(3)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Composite endpoint (death, nonfatal cardiovascular event, transfer to hemodialysis)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Blood pressure
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Quality of life
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: 6-minute walk test
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Inflammatory and fibrotic markers
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Residual renal function
Number of subjects: 70
Study: 20027096

Group type: EXPERIMENTAL
Intervention: Midline approach between the peritoneum and the posterior rectus sheath (MP)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Midline approach between the rectus muscle and the posterior rectus sheath (MR)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Lateral approach between the rectus muscle and the posterior rectus sheath (LR)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Lateral approach between the peritoneum and the posterior rectus sheath (LP)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Lateral approach groups (LR and LP)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Midline approach groups (MR and MP)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Postoperative analgesics
Number of subjects: 99
Study: 17062774

Group type: EXPERIMENTAL
Intervention: GH-treated subjects
Number of subjects: 62

Group type: COMPARATOR
Intervention: Untreated controls
Number of subjects: 62
Study: 15314531

Group type: EXPERIMENTAL
Intervention: Computer-aided training
Number of subjects: 274

Group type: COMPARATOR
Intervention: Conventional training
Number of subjects: 274
Study: 11597802

Group type: EXPERIMENTAL
Intervention: Oral sucralfate (3 g suspension, twice a day during radiotherapy)
Number of subjects: 335

Group type: COMPARATOR
Intervention: Placebo (twice a day during radiotherapy)
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: Oral sucralfate
Number of subjects: 335

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 335
Study: 9834047

Group type: EXPERIMENTAL
Intervention: Anticonvulsant drugs (specific drugs not mentioned)
Number of subjects: 0
Study: 8003559

Group type: EXPERIMENTAL
Intervention: Thiotepa 450‐750 mg/m2, busulfan 10 or 12 mg/kg, and cyclophosphamide 120 or 150 mg/kg
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Higher busulfan dose
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Zubrod performance status of 2 or 3
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Ten or more previous cycles of chemotherapy
Number of subjects: 127
Study: 2589355

Group type: EXPERIMENTAL
Intervention: Oral ciprofloxacin
Number of subjects: 25

Group type: COMPARATOR
Intervention: Intravenous tobramycin and azlocillin
Number of subjects: 25
Study: 913868

Group type: EXPERIMENTAL
Intervention: Delta‐Butazolidin (phenylbutazone 50 mg + prednisone 1.25 mg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Prednisone 1.25 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 30312839

Group type: EXPERIMENTAL
Intervention: Ketamine (0.5 mg/kg over 40 minutes)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 27471840

Group type: EXPERIMENTAL
Intervention: Prophylactic augmentation with retro-muscular lightweight polypropylene mesh
Number of subjects: 150

Group type: COMPARATOR
Intervention: Conventional colostomy formation (nonmesh group)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Both groups (mesh and nonmesh)
Number of subjects: 150
Study: 25988261

Group type: EXPERIMENTAL
Intervention: Single dose of 1500 mg quercetin
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Short-term administration of 1500 mg quercetin daily for 1 week
Number of subjects: 10

Group type: COMPARATOR
Intervention: Intravenous administration of midazolam
Number of subjects: 10
Study: 22965329

Group type: EXPERIMENTAL
Intervention: ramosetron
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: dexamethasone
Number of subjects: 123

Group type: COMPARATOR
Intervention: control (NaCl)
Number of subjects: 123
Study: 22129483

Group type: EXPERIMENTAL
Intervention: CP children
Number of subjects: 3

Group type: COMPARATOR
Intervention: Healthy children
Number of subjects: 3

Group type: COMPARATOR
Intervention: Healthy adults
Number of subjects: 3
Study: 19500787

Group type: EXPERIMENTAL
Intervention: 7-day low-dose omeprazole infusion (3.3 mg/h)
Number of subjects: 147

Group type: COMPARATOR
Intervention: 3-day high-dose omeprazole infusion (8 mg/h)
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: 7-day low-dose omeprazole infusion
Number of subjects: 147
Study: 16514327

Group type: EXPERIMENTAL
Intervention: Lidocaine 5 mg/kg/h
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lidocaine 1 mg/kg/h
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lidocaine 3 mg/kg/h
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lidocaine (all doses)
Number of subjects: 0
Study: 12626987

Group type: EXPERIMENTAL
Intervention: Cuffed oropharyngeal airway
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Combitube
Number of subjects: 48

Group type: COMPARATOR
Intervention: Bag-valve-mask
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Cuffed oropharyngeal airway, Laryngeal mask airway, Combitube
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Bag-valve-mask, Cuffed oropharyngeal airway
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: All airway devices
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: All airway devices with 100% oxygen
Number of subjects: 48
Study: 11085201

Group type: EXPERIMENTAL
Intervention: Fluvoxamine 100 to 300 mg/day for 6 to 10 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fluvoxamine ≤300 mg/day for 6 to 8 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fluvoxamine ≤300 mg/day for ≥8 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fluvoxamine
Number of subjects: 0
Study: 9200054

Group type: EXPERIMENTAL
Intervention: Mammography screening
Number of subjects: 2

Group type: COMPARATOR
Intervention: Control (unscreened population)
Number of subjects: 2
Study: 8397881

Group type: EXPERIMENTAL
Intervention: Alcohol subjects received sufficient alcohol to raise their blood alcohol level to .07 mg %
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control group (not explicitly detailed in the abstract)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Peak intoxication level
Number of subjects: 96
Study: 3453187

Group type: EXPERIMENTAL
Intervention: Diuretics (mainly chlorthalidone)
Number of subjects: 7006

Group type: COMPARATOR
Intervention: Untreated group
Number of subjects: 7006
Study: 31851240

Group type: EXPERIMENTAL
Intervention: Hammock position
Number of subjects: 20

Group type: COMPARATOR
Intervention: Nesting position
Number of subjects: 20
Study: 29392743

Group type: EXPERIMENTAL
Intervention: PPD 1% pet. (6 mg)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: PPD 0.3% pet. (20 mg)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Both doses (PPD 1% and PPD 0.3%)
Number of subjects: 17
Study: 26866638

Group type: EXPERIMENTAL
Intervention: Active medication (MED; n = 50)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Supportive-expressive therapy (SET; n = 49)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Placebo pill (PBO; n = 50)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: All conditions (MED, SET, PBO)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Supportive-expressive therapy (SET)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Active medication (MED)
Number of subjects: 149
Study: 25448672

Group type: EXPERIMENTAL
Intervention: IBPB associated with Intravenous‐inhalation combined anesthesia (group NB)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Intravenous‐inhalation combined anesthesia (group CI)
Number of subjects: 100
Study: 21789517

Group type: EXPERIMENTAL
Intervention: Laparoscopic-assisted vaginal hysterectomy (LAVH)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Non-descent vaginal hysterectomy (NDVH)
Number of subjects: 20
Study: 20173709

Group type: EXPERIMENTAL
Intervention: Antiseptic mouth-rinse containing chlorhexidine and cetylpyridinium chloride
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 18161933

Group type: EXPERIMENTAL
Intervention: Partial splenic embolization (PSE) combined with transcatheter hepatic arterial chemoembolization (TACE)
Number of subjects: 50

Group type: COMPARATOR
Intervention: TACE alone
Number of subjects: 50
Study: 16451305

Group type: EXPERIMENTAL
Intervention: Chemical agents incorporated in dentifrice or mouth rinse formulations
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 12847372

Group type: EXPERIMENTAL
Intervention: 0.2 percent glyceryl trinitrate ointment
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo ointment
Number of subjects: 110
Study: 11938776

Group type: EXPERIMENTAL
Intervention: Carvedilol (10mg to 40mg once daily)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Atenolol (50mg to 100mg once daily)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Carvedilol (Group A)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Atenolol (Group B)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both groups (Carvedilol and Atenolol)
Number of subjects: 80
Study: 9031394

Group type: EXPERIMENTAL
Intervention: Regimen-I: artemether (300 mg) plus pyrimethamine (100 mg) on the first day, then placebo on the two consecutive days
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Regimen-II: artemether (300 mg) plus pyrimethamine (100 mg) on the first day, then artemether (150 mg) plus pyrimethamine (50 mg) on the second day, and placebo on the third day
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Regimen-III: artemether (300 mg) plus pyrimethamine (100 mg) on the first day, then artemether (150 mg) plus pyrimethamine (50 mg) on the second and third days
Number of subjects: 60
Study: 1285244

Group type: EXPERIMENTAL
Intervention: Urinary trypsin inhibitory activity
Number of subjects: 690

Group type: COMPARATOR
Intervention: C-Reactive protein
Number of subjects: 690
Study: 6347753

Group type: EXPERIMENTAL
Intervention: Flurbiprofen (50 mg four times a day)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 31254226

Group type: EXPERIMENTAL
Intervention: Vitamin E-bonded polysulfone membrane hemodialyzer (ViE™‐21)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Conventional high‐flux hemodialyzers
Number of subjects: 17
Study: 30107480

Group type: EXPERIMENTAL
Intervention: Lifestyle education - dyad group (both women and husbands)
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Lifestyle education - women only group
Number of subjects: 189

Group type: COMPARATOR
Intervention: Control group (routine care)
Number of subjects: 189
Study: 27075914

Group type: COMPARATOR
Intervention: Sodium nitrate (NaNO3)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Concentrated beetroot juice
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Rocket salad beverage
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Spinach beverage
Number of subjects: 18
Study: 24532525

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.2 μg/(kg·h)⁻¹)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 96
Study: 23422630

Group type: EXPERIMENTAL
Intervention: 6% triphala mouthwash, 15 ml twice a day
Number of subjects: 60

Group type: COMPARATOR
Intervention: 0.2% chlorhexidine mouthwash, 15 ml twice a day
Number of subjects: 60

Group type: COMPARATOR
Intervention: Plain water rinse, twice a day
Number of subjects: 60
Study: 20347681

Group type: EXPERIMENTAL
Intervention: Intermittent mechanical compression (IMC) applied at 65 mm Hg for two hours/day for three months.
Number of subjects: 30

Group type: COMPARATOR
Intervention: Best medical treatment (BMT) alone.
Number of subjects: 30
Study: 17908626

Group type: EXPERIMENTAL
Intervention: Involved-node radiotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Early positron emission tomography scan with fluorodeoxyglucose
Number of subjects: 0
Study: 16274477

Group type: EXPERIMENTAL
Intervention: Topical ibuprofen
Number of subjects: 283

Group type: COMPARATOR
Intervention: Oral ibuprofen
Number of subjects: 283
Study: 12358658

Group type: EXPERIMENTAL
Intervention: Intramuscular clonidine (2 microg x kg(‐1))
Number of subjects: 39

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 39
Study: 10199426

Group type: EXPERIMENTAL
Intervention: Rapid defibrillation program optimization (including defibrillation by firefighters, base paging, tiered response agreements, continuous quality improvement, and standard dispatch policies)
Number of subjects: 6331
Study: 7539270

Group type: EXPERIMENTAL
Intervention: FK 506
Number of subjects: 47

Group type: COMPARATOR
Intervention: Cyclosporin
Number of subjects: 47
Study: 1688913

Group type: EXPERIMENTAL
Intervention: Dextran 40 (500 ml per session) during 3 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo treatments for 3 weeks
Number of subjects: 20
Study: 7387900

Group type: EXPERIMENTAL
Intervention: Prednisolone 40 mg daily with gradual reduction over a period of 4 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Carbamazepine 100 mg four times daily
Number of subjects: 40
Study: 30529393

Group type: EXPERIMENTAL
Intervention: Auricular acupuncture
Number of subjects: 153

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 153

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 153
Study: 29061430

Group type: EXPERIMENTAL
Intervention: Learning through Play Plus program (LTP Plus)
Number of subjects: 247

Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 247
Study: 26303700

Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 24415640

Group type: EXPERIMENTAL
Intervention: Chlorambucil plus rituximab (CLB-R)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Rituximab maintenance (375 mg/m2, 12 doses)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Observation (control group)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Chlorambucil (8 mg/m2/day, days 1-7) and Rituximab (375 mg/m2 on day 1 of cycle 3, 500 mg/m2 for cycles 4-8)
Number of subjects: 85
Study: 22829268

Group type: EXPERIMENTAL
Intervention: Donepezil 5 mg/day
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Donepezil 10 mg/day
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Donepezil 3 mg/day
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Donepezil 5 mg/day and 10 mg/day
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study: 19193706

Group type: EXPERIMENTAL
Intervention: Probiotic yogurt containing Bifidobacterium animalis subsp. lactis DN-173010 (2 x 10(8) CFU/g), 200 g once daily for 2 weeks
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control yogurt without viable bacteria, 200 g once daily for 2 weeks
Number of subjects: 24
Study: 17185016

Group type: EXPERIMENTAL
Intervention: Intravenous ketoprofen 1mg/kg i.v. at skin closure, and at 8 and 16 hours after surgery
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Intravenous ketoprofen
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 31
Study: 14975544

Group type: EXPERIMENTAL
Intervention: Folic acid 5 mg o.d. added to statin therapy (fluvastatin 40 mg)
Number of subjects: 283

Group type: COMPARATOR
Intervention: Control group (statin therapy only)
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Folic acid 5 mg o.d. added to statin therapy
Number of subjects: 283
Study: 11223689

Group type: EXPERIMENTAL
Intervention: Antiandrogen withdrawal
Number of subjects: 44